TIGIT is a negative regulator of innate and adaptive immune responses. AGEN1327 is a fully human monoclonal antibody that boosts the immune response to cancer cells by blocking the interaction between TIGIT and its binding partner CD155. Moreover, AGEN1327 is one of our next-generation antibodies which has been “Fc enhanced” to maximize antitumor activity (see AGEN1181). Therefore, we expect that AGEN1327 will bring clinical benefit above and beyond that of conventional anti-TIGIT antibodies. TIGIT signaling has also been identified as a key resistance mechanism to anti-PD-1 therapy, suggesting that AGEN1327 can address therapeutic resistance to anti-PD-1 therapy.

Latest Publications and Abstracts

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity. Ward, et al.

American Association for Cancer Research (AACR)

March 29-April 3, 2019

FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses. Chand, et al.

Cancer Cell

June 11, 2018

Selective FcgR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Waight, et al.